Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 19/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 13/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 0.74 |
| ▸ | IL1B | P01584 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thalidomide SCHEMBL7581 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL410642 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL15197560 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL41641 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL571278 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411178 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411175 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL23420695 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL22772286 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL19586750 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | claimed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | claimed |
| EP-1521708-B2 | A METHOD OF PROVIDING A PACKAGE WITH A BARRIER AND THE PACKAGE THUS OBTAINED | TETRA LAVAL HOLDINGS & FINANCE (CH) | 2015-03-18 | — | — | EP | claimed |
| EP-1941109-A1 | BUILDING BLOCK | Lund, Svein (NO) | 2008-07-09 | — | — | EP | claimed |
| WO-2006110045-A1 | BUILDING BLOCK | LUND SVEIN (NO) | 2006-10-19 | — | — | WO | claimed |
| WO-2002023803-A1 | INFORMATION DELIVERY SYSTEM, METHOD FOR INFORMATION DELIVERY, SERVICE PRODUCT AND USE OF THE SERVICE PRODUCT | PORTALIFY OY (FI) | 2002-03-21 | — | — | WO | claimed |
| EP-0959865-A2 | SAUNA VENTILATION AND FIRE PREVENTION SYSTEM | Komulainen, Jorma (FI) | 1999-12-01 | — | — | EP | claimed |
| WO-1998010173-A1 | TRANSMISSION UNIT FOR A ROTARY PISTON ENGINE | AUVINEN RISTO (FI) | 1998-03-12 | — | — | WO | claimed |
| WO-1997034562-A2 | SAUNA VENTILATION SYSTEM | KOMULAINEN JORMA (FI) | 1997-09-25 | — | — | WO | claimed |
| JP-5290217-A | — | — | None | — | — | JP | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260132108-A1 | PREPARATION OF MESEMBRINE | KANNA HEALTH LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-2002010202-A2 | G-PROTEIN COUPLED RECEPTORS AND NUCLEIC ACIDS ENCODING SAME | CURAGEN CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| US-5426712-A | Method and apparatus for describing a character image based on its contours, and for classifying the character image for character recognition based on a resulting contour-based description of the character image | RICOH COMPANY, LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| JP-H05290217-A | CHARACTER RECOGNITION METHOD | RICOH CO LTD | 1993-11-05 | — | — | JP | disclosed |
| US-5064872-A | Alone or with another gas; closed-cell; fireproofing, thermol insulation; pollution control | RECTICEL (BE) | 1991-11-12 | — | — | US | disclosed |
| US-4270530-A | Tracheal tube | DRAGERWERK AKTIENGESELLSCHAFT (DE) | 1981-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | CRBN 11/4885DDB1 279/4885IKZF3 1051/4885 |
| US-20260132108-A1 | PREPARATION OF MESEMBRINE | BHMT, TMSB10, MSMO1 | CRBN 4301/4885DDB1 686/4885IKZF3 4365/4885 |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | CRBN 2467/4885DDB1 2613/4885IKZF3 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.